340B Oversight Gathering Steam In Senate; HELP Committee Plans Hearing
Executive Summary
With several pieces of legislation in play that could overhaul 340B transparency and oversight, hospitals and sponsors will have a lot on the line during Senate hearing planned for 'early spring.'
You may also be interested in...
340B Provider Reforms Gaining Momentum In Congress
House Energy & Commerce Committee recommends more oversight of hospital participation in the 340B drug discount program.
Medicare Part D Redesign Could Expand Rebate-Driven Formulary Exclusions In Program
Increased application of utilization management controls expected as plans face higher costs under the redesign. However, the formulary advantages available to drugs in the protected classes may lead developers to sharpen their focus on those categories.
Leqembi Label Recommends Alzheimer’s Patient Registry: A Nod To Medicare Evidence Demands?
FDA-approved language recommending ongoing patient monitoring through a registry is unusual but not unprecedented to address potential safety concerns.